Latest News Glenn P. Sblendorio to Join Ophthotech as Executive VP, COO and CFO By Staff Friday, January 8, 2016 12:18 AM NEW YORK—Ophthotech Corporation (NASDAQ: OPHT) announced that Glenn P. Sblendorio, a leading industry veteran, has agreed to join the company as executive vice president, chief operating officer and chief financial officer on April 1, 2016. Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases.Ophthotech also announced today that Michael G. Atieh is retiring as executive vice president and chief financial and business officer of the company. The company expects that Atieh’s retirement will be effective as of April 1, 2016.Sblendorio is joining Ophthotech from The Medicines Company, where he most recently served as president and chief financial officer. He has more than 30 years of experience in the life sciences sector and is widely known in the investment community and the biotechnology / pharmaceutical industry. He has held a variety of senior management positions at Hoffmann-LaRoche, Inc., Eyetech Pharmaceuticals Inc. and MPM Capital Advisors, LLC. Sblendorio has served as a member of the board of directors and the audit committee chairman of Ophthotech. He will resign as a director of Ophthotech effective with the assumption of his new executive position, and effective immediately. “Glenn is an accomplished leader in the healthcare industry with extensive financial, operational and business development experience,” said David R. Guyer, MD, chief executive officer and chairman of the board of Ophthotech. “Samir Patel and I had the great pleasure of working with Glenn in the past at Eyetech and we are delighted to reunite with him as a key member of Ophthotech’s management team,” he said.